CINCINNATI--(BUSINESS WIRE)--Jul. 7, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced
today that FORTUNE Small Business has ranked Meridian Bioscience, Inc.
number 34 on their ninth annual FSB 100 list of the fastest growing
small public companies in America. The list appears in the July/August
issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2009/.
To compile the ninth annual list, FORTUNE Small Business asked financial
research firm Zacks to rank public companies with revenues less than
$200 million and a stock price of more than $1 by their three-year
annualized rate of revenue growth and return to investors.
John A. Kraeutler, Chief Executive Officer, stated, "For the fifth year
in a row Meridian Bioscience has been ranked among the top 100 fastest
growing companies by FORTUNE Small Business magazine. This
acknowledgement is sincerely appreciated. Our performance in delivering
shareholder value, while helping improve the diagnosis of disease, is
directly due to our outstanding employees and our valuable customers
around the globe."
Meridian is a fully integrated life science company that manufactures,
markets and distributes a broad range of innovative diagnostic test
kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics manufacturers
and biotech companies in more than 60 countries around the world. The
Company’s shares are traded through NASDAQ’s Global Select Market,
symbol VIVO. Meridian's website address is www.meridianbioscience.com.
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
John A. Kraeutler, CEO, 513-271-3700